GL1X · GenesisL1 explorer

Research workbench

Crystal structure of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds

Analyse Crystal structure of potent human dihydroorotate dehydrogenase inhibitors based… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5MVC
Type
protein
Length
352 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dihydroorotate dehydrogenase (quinone), mitochondrial
EC
1.3.5.2
UniProt
Q02127
Ligands
FMN, ORO, Y9B, CL
Pockets
4 · best druggability 0.83

Structure

x-ray diffraction · 1 distinct chain · 47% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADihydroorotate dehydrogenase (quinone), mitochondrial (EC 1.3.5.2)protein35247% helix, 17% strandQ02127

Ligands and binding sites

  • FMN · Flavin mononucleotide · ligand · chains A
  • ORO · Orotic acid · ligand · chains A
  • Y9B · 4-oxidanyl-~{N}-[2,3,5,6-tetrakis(fluoranyl)-4-phenyl-phenyl]-1,2,5-thiadiazole-3-carboxamide · ligand · chains A
  • CL · Chloride ion · ion · 5 copies · chains A
  • ACT · Acetate ion · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14600.830.9070FMN, ORO, Y9B
21020.440.7920ACT
31110.390.7518empty
4720.370.7819empty

Compared structures

  • 5MVC · Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.